Compare CGEN & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEN | MRCC |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 133.2M |
| IPO Year | 2000 | 2012 |
| Metric | CGEN | MRCC |
|---|---|---|
| Price | $1.48 | $6.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 405.6K | 132.1K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 11.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,903,000.00 | ★ $43,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $231.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $5.86 |
| 52 Week High | $2.66 | $8.85 |
| Indicator | CGEN | MRCC |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 41.65 |
| Support Level | $1.47 | $5.99 |
| Resistance Level | $1.55 | $6.80 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 16.98 | 33.13 |
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.